http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 11:05:56 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/New+Coverage/Barclays+Starts+Cellectis+%28CLLS%29+at+Overweight/26560062.html (Updated - May 28, 2026 3:43 AM EDT) <p>Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ: CLLS) with a Overweight rating and a price target of $9.00.</p><p>The analyst comments: “We initiate coverage of Cellectis (CLLS) at Overweight with a $9 price target. Cellectis is a biopharamceutical company focused on the development of allogenic CAR-T therapeutics for various cancers. The company's allogenic platform allows for potentially quicker reaction time from diagnosis to treatment than autologous CAR-T therapies, opening up treatment settings that were previously inaccessible, like frontline consolidation in liquid tumors. Lead asset Lasme-cel is a CD22 allogenic CAR-T program being http://www.streetinsider.com/New+Coverage/Barclays+Starts+Cellectis+%28CLLS%29+at+Overweight/26560062.html Thu, 28 May 2026 03:43:01 -0400 CLLS http://www.streetinsider.com/Analyst+Comments/Barclays+Starts+Cellectis+%28CLLS%29+at+Overweight/26560062.html (Updated - May 28, 2026 3:43 AM EDT) <p>Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ: CLLS) with a Overweight rating and a price target of $9.00.</p><p>The analyst comments: “We initiate coverage of Cellectis (CLLS) at Overweight with a $9 price target. Cellectis is a biopharamceutical company focused on the development of allogenic CAR-T therapeutics for various cancers. The company's allogenic platform allows for potentially quicker reaction time from diagnosis to treatment than autologous CAR-T therapies, opening up treatment settings that were previously inaccessible, like frontline consolidation in liquid tumors. Lead asset Lasme-cel is a CD22 allogenic CAR-T program being http://www.streetinsider.com/Analyst+Comments/Barclays+Starts+Cellectis+%28CLLS%29+at+Overweight/26560062.html Thu, 28 May 2026 03:43:01 -0400 CLLS http://www.streetinsider.com/Earnings/Cellectis+%28CLLS%29+Tops+Q1+EPS+by+8c/26470066.html <p>Cellectis (NASDAQ: CLLS) reported Q1 EPS of ($0.18), $0.08 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.02 million versus the consensus estimate of $13.02 million.</p><p>For earnings history and earnings-related data on Cellectis (CLLS) <a href="http://www.streetinsider.com/ec_earnings.php?q=CLLS">click here</a>.</p> http://www.streetinsider.com/Earnings/Cellectis+%28CLLS%29+Tops+Q1+EPS+by+8c/26470066.html Mon, 11 May 2026 16:45:43 -0400 CLLS http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Press+Releases/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930 http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html <p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation of the forthcoming launch of Interoc’s CIBUS® enhanced seed products into the Latin American agricultural sector.</p> <p>“Our collaboration with Cibus continues to deliver significant value,” said Fernando De La Puente, Corporate Vice President at Interoc. “Rice is a critical crop for http://www.streetinsider.com/Globe+Newswire/Cibus+Announces+Transfer+of+Gene-Edited+Herbicide+Tolerance+Traits+in+Interoc+Rice+Seeds+for+Testing+and+Production/26420773.html Mon, 04 May 2026 07:00:00 -0400 A.50205015 A.50210275 ALCLS CBUS CLLS O.00652080 O.10892317 O.26348945 O.31525930